Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPC

Reuters2026/08/24 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Monte Rosa Therapeutics dosed the first patient in MODeFIRe-1, a Phase 2 trial of MRT-2359 with apalutamide in AR mutation-positive mCRPC.
Trial aims to confirm earlier signs of anti-tumor activity in a hard-to-treat group with limited options.
Prior interim results from a Phase 1/2 study of MRT-2359 with enzalutamide were presented in February at ASCO GU.
Updated data from that Phase 1/2 combination study are expected by end of year, a key near-term catalyst.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240700PRIMZONEFULLFEED9814358) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPC

You may also like

Crypto prices